Business
AstraZeneca COVID-19 vaccine trial data results in revised efficacy rate – The Motley Fool Australia
AstraZeneca PLC (LON: AZN) has revised its COVID-19 vaccine efficacy rating after concluding a more extensive study previously done.
Home / Coronavirus News / AstraZeneca COVID-19 vaccine trial data results in revised efficacy rateThe Oxford-AstraZeneca PLC (LON: AZN) COVID-19 vaccine has travelled a bumpy road through its development and rollout. Marred with accusations of the vaccine causing blood clots, regulatory and government pressures have weighed on the drug developer and its acceptance.
According to the latest press release from AstraZeneca, the company has revised the vaccine’s efficacy from 79% to 76%, following…
-
Noosa News8 hours agoShocking moment Bradley Donald Towle arrested after Bruce Hwy rampage and shooting on Sunshine coast
-
Noosa News15 hours agoMollie O’Callaghan admits to doubts, wins gold at Australian Open Swimming Championships
-
General9 hours agoNSW Police to provide update on Sydney woman’s kidnap from Bankstown home and killing
-
General24 hours agoPope Francis, the 266th pope, has died